Abstracts tagged "giant cell arteritis"

Abstract Number: 1627 • ACR Convergence 2024
Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study
Nobuhiro Oda¹, Sho Fukui², Toshihiro Yamaguchi³, Fumika Nagase⁴, Takanori Ito⁵, Mitsuru Watanabe⁵, Yoichiro Haji⁴, Yasuhiro Suyama⁶, Atsushi Nomura⁷, Eishi Uechi⁸, Masei Suda³, Naoho Takizawa⁴, Ryo Rokutanda⁹ and Hiromichi Tamaki¹⁰, ¹Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, ⁴Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, ⁵Daido Hospital, Department of Rheumatology, Aichi, Japan, ⁶NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, ⁷Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, ⁸Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, ⁹Kameda medical center, Department of Rheumatology, Chiba, Japan, ¹⁰St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan
Background/Purpose: In the 2022 ACR classification criteria for giant cell arteritis (GCA), temporal artery ultrasound (TAU) is granted the same diagnostic value as temporal artery…
Abstract Number: 2501 • ACR Convergence 2024
Long-term Remission off Therapy (LTROT) Is Possible in Non-infectious Aortitis with DMARDs with Low Risk of Secondary Adrenal Insufficiency
Rohit Vijjhalwar¹, Vithushanan Ketheeswaranathan², Aman More², Rajinder Andev³ and Shirish Dubey⁴, ¹University of Oxford, Staines, United Kingdom, ²Medical Sciences Division, University of Oxford, Oxford, United Kingdom, ³Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom
Background/Purpose: Non-infectious Aortitis is a rare form of large vessel vasculitis which has a high risk of complications1. There is limited data on the management…
Abstract Number: 0752 • ACR Convergence 2024
Non-classical Organ Involvement in Giant Cell Arteritis
Javier Narvaez-García¹, paola Vidal¹, Pol Maymó², Judith Palacios³, Martí Aguilar Coll¹, Monserrat Roig Kim¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge., Barcelona, Spain, ³Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The increasing use of imaging techniques, particularly 18F-FDG PET-CT, has significantly expanded our understanding of giant cell arteritis (GCA). Our aim was to examine…
Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Clara Moriano⁴, Javier Narvaez-García⁵, Vicente Aldasoro⁶, Olga Maíz Alonso⁷, Iñigo Hernández-Rodríguez⁸, Paloma Vela-Casasempere⁹, Susana Romero Yuste¹⁰, Eugenio De Miguel¹¹, Eva Galindez-Agirregoikoa¹², Jesus C. Fernandez-López¹³, ivan Ferraz-Amaro¹⁴, Julio Sánchez-Martín¹⁵, José Luis Callejas¹⁶, Patricia Moya Albarado¹⁷, Cristina Campos Fernández¹⁸, Fernando Lopez-Gutierrez¹⁹, Santos Castañeda²⁰ and Ricardo Blanco-Alonso²¹, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital León, LEON, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁸Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario La Paz, Madrid, Spain, ¹²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹³11Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, ¹⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁷Hospital de San Pau, Barcelona, Spain, ¹⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²⁰Hospital Universitario de la Princesa, Madrid, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
Abstract Number: 1628 • ACR Convergence 2024
Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study
Nobuhiro Oda¹, Sho Fukui², Toshihiro Yamaguchi³, Fumika Nagase⁴, Takanori Ito⁵, Mitsuru Watanabe⁵, Yoichiro Haji⁴, Yasuhiro Suyama⁶, Atsushi Nomura⁷, Eishi Uechi⁸, Masei Suda³, Naoho Takizawa⁴, Ryo Rokutanda⁹ and Hiromichi Tamaki¹⁰, ¹Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, ⁴Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, ⁵Daido Hospital, Department of Rheumatology, Aichi, Japan, ⁶NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, ⁷Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, ⁸Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, ⁹Kameda medical center, Department of Rheumatology, Chiba, Japan, ¹⁰St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan
Background/Purpose: The GiACTA trial, a phase III global trial of tocilizumab (TCZ) for giant cell arteritis (GCA), did not involve Japanese patients, and real-world data…
Abstract Number: 2511 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Patients with Clinically Isolated Aortitis
Mahmut Kaymakci¹, Hannah Langenfeld¹, Andrew C. Hanson², Cynthia Crowson¹, Melanie Bois¹, Hartzell Schaff², Mohanad Elfishawi³, Matthew Koster¹, Cornelia Weyand² and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³University of Minnesota, Minneapolis
Background/Purpose: Clinically Isolated Aortitis (CIA) is a type of vasculitis affecting the aorta in the absence of systemic vasculitis, rheumatic disease, or infection. Most patients…
Abstract Number: 0753 • ACR Convergence 2024
Treatment and Evolution in 134 Patients with Aortitis and Periaortitis. Experience of a Single Referral Centre
Carmen Secada Gómez¹, Javier Loricera², Adrián Martín-Gutiérrez³, Fernando Lopez-Gutierrez⁴, Santos Castañeda⁵ and Ricardo Blanco-Alonso⁶, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis and periaortitis include a heterogeneous group of entities that may be idiopathic or secondary to infectious and non-infectious processes. Therefore, treatment will differ…
Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
Abstract Number: 1629 • ACR Convergence 2024
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Sharon Cowley¹, Patricia Harkins², Colm Kirby³, Richard Conway⁴, David Kane⁵, Rositsa Karalilova⁶, Pierluigi Macchioni⁷, Christina Ponte⁸, Edoardo Conticini⁹, Alessandro Tomelleri¹⁰, Sara Monti¹¹, irene monjo¹², Zguro Batalov¹³, Giulia Klinowski⁷, Paolo Falsetti¹⁴, Corrado Campochiaro¹⁵, Alojzija Hocevar¹⁶ and Eugenio De Miguel¹⁷, ¹Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ²Trinity College Dublin, Dublin 8, Dublin, Ireland, ³Tallaght University Hospital, DUBLIN, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁷Rheumatology Department, Ospedale S Maria Nuova, Reggio Emilia, Italy, Emilia, Italy, ⁸Rheumatology, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, Lisboa, Portugal, ⁹Università di Siena, Siena, Italy, ¹⁰Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ¹¹IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹²University Hospital La Paz, Madrid, Spain, ¹³Rheumatology, University Hospital Kaspela, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ¹⁴Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy, Siena, Italy, ¹⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁶University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁷Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Subclinical GCA in PMR has been estimated to affect 1 in 5 patients as assessed by vascular ultrasound [1, 2]. This study compared the ultrasound…
Abstract Number: 2520 • ACR Convergence 2024
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Peter Merkel¹, Yi Peng², Patrick Zueger², Clara Ziadeh³, Ana B. Romero⁴, Richard Thielen³ and Denise Kruzikas³, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc, North Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
Abstract Number: 0754 • ACR Convergence 2024
Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Carmen Secada Gómez¹, Javier Loricera², Adrián Martín-Gutiérrez³, Fernando Lopez-Gutierrez⁴, María Nuñez-Sayar⁵, Ander Ucelay-Aristi⁵, Isabel Martinez-Rodriguez⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco-Alonso⁹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁵Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis and periaortitis represent the inflammation of the aortic wall and the surrounding periaortic tissues, respectively. Both can be idiopathic or secondary to infectious…
Abstract Number: 1612 • ACR Convergence 2024
Arterial Involvement Distribution on 18FFDG PET-CT in Giant Cell Arteritis: Variances Based on Clinical Phenotype
paola Vidal¹, Javier Narvaez-García¹, Ivan Sánchez-Rodríguez¹, Aida Sabaté-Llobera¹, Montserrat Cortés-Romera¹, Judith Palacios², Pol Maymó³, Monserrat Roig Kim¹, Martí Aguilar Coll¹, Laia De Daniel¹ and Joan Miquel Nolla¹, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain
Background/Purpose: Current evidence shows that giant cell arteritis (GCA) is much more than a cranial disease, as it has a much broader and heterogeneous clinical…
Abstract Number: 1630 • ACR Convergence 2024
Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic
Uffe Moller Dohn¹, Tanja Fromberg Gorlen², Rikke Westergaard¹, Viktoria Fana¹, Torsten Møller¹ and Lene Terslev³, ¹Rigshospitalet-Glostrup, Glostrup, Denmark, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting the large vessels from aorta, its proximal branches, and the extra-cranial arteries. To avoid ischemic…
Abstract Number: 2521 • ACR Convergence 2024
Clinicopathologic Associations Between Macrophage Location and Functional Profile in Giant Cell Arteritis
Michael Putman¹, Nader Khalidi², Carol Langford³, Curry Koening⁴, Christian Pagnoux⁵, David Cuthbertson⁶, Carol McAlear⁷ and Peter Merkel⁷, and the Vasculitis Clinical Research Consortium (VCRC), ¹The Medical College of Wisconsin, Milwaukee, WI, ²McMaster University, Hamilton, ON, Canada, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Texas Dell Medical School, Austin, TX, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶University of South Florida, Tampa, FL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Macrophages play a central role in the pathogenesis of giant cell arteritis (GCA), but few studies have correlated macrophage phenotype or topography from temporal…
Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Ali Raza Khan¹, Nouman Shafique², Abdul Qadeer¹ and zaigham Shaukat¹, ¹Nishtar Medical University, Multan, Punjab, Pakistan, ²AdventHealth Orlando, Orlando, FL
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].